Literature DB >> 2495775

Intestinal permeability in Crohn's disease.

M S Murphy1, E J Eastham, R Nelson, A D Pearson, M F Laker.   

Abstract

Crohn's disease may present insidiously, especially in childhood, and diagnosis may be delayed. In addition, the clinical assessment of the extent of disease activity may be inaccurate. Using mannitol and lactulose as probe molecules we have carried out a cross sectional study of intestinal permeability in patients with active Crohn's disease (n = 17) and control subjects (n = 31). Activity was assessed by an activity index score. The lactulose:mannitol urinary excretion ratio was significantly increased in Crohn's disease. Overall sensitivity was 82%, and 92% when activity was moderate or severe. When permeability was compared with the activity index there was a significant correlation among patients. In five patients studied longitudinally a significant correlation was also present. Measurement of intestinal permeability is non-invasive, and may be useful both as a screening test in patients with non-specific symptoms, and for the assessment of the extent of disease activity in patients with Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495775      PMCID: PMC1791927          DOI: 10.1136/adc.64.3.321

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  21 in total

1.  IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease.

Authors:  F T de Dombal; A Softley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

2.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

3.  Estimation of disaccharides in plasma and urine by gas-liquid chromatography.

Authors:  M F Laker
Journal:  J Chromatogr       Date:  1979-05-01

4.  Intestinal permeability assessed by excretion ratios of two molecules: results in coeliac disease.

Authors:  I Cobden; R J Dickinson; J Rothwell; A T Axon
Journal:  Br Med J       Date:  1978-10-14

5.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

6.  Mannitol estimation in biological fluids by gas-liquid chromatography of trimethylsilyl derivatives.

Authors:  M F Laker; J N Mount
Journal:  Clin Chem       Date:  1980-03       Impact factor: 8.327

7.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

8.  Intestinal permeability in children with Crohn's disease and coeliac disease.

Authors:  A D Pearson; E J Eastham; M F Laker; A W Craft; R Nelson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-03

9.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

10.  Intestinal permeability and screening tests for coeliac disease.

Authors:  I Cobden; J Rothwell; A T Axon
Journal:  Gut       Date:  1980-06       Impact factor: 23.059

View more
  15 in total

Review 1.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

2.  Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host.

Authors:  Samuel M Alaish; Alexis D Smith; Jennifer Timmons; Jose Greenspon; Daniel Eyvazzadeh; Ebony Murphy; Terez Shea-Donahue; Shana Cirimotich; Emmanuel Mongodin; Aiping Zhao; Alessio Fasano; James P Nataro; Alan Cross
Journal:  Gut Microbes       Date:  2013-04-15

Review 3.  New molecular insights into inflammatory bowel disease-induced diarrhea.

Authors:  Yueming Tang; Christopher B Forsyth; Ali Keshavarzian
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-10       Impact factor: 3.869

Review 4.  Adaptation of intestinal nutrient transport in health and disease. Part II.

Authors:  A B Thomson; G Wild
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

5.  Small intestinal permeability and orocaecal transit time in cystic fibrosis.

Authors:  A M Dalzell; N S Freestone; D Billington; D P Heaf
Journal:  Arch Dis Child       Date:  1990-06       Impact factor: 3.791

6.  Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.

Authors:  T Oriishi; M Sata; A Toyonaga; E Sasaki; K Tanikawa
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

Review 7.  Cytoskeletal regulation of epithelial barrier function during inflammation.

Authors:  Andrei I Ivanov; Charles A Parkos; Asma Nusrat
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

8.  Matriptase protects against experimental colitis and promotes intestinal barrier recovery.

Authors:  Sarah Netzel-Arnett; Marguerite S Buzza; Terez Shea-Donohue; Antoine Désilets; Richard Leduc; Alessio Fasano; Thomas H Bugge; Toni M Antalis
Journal:  Inflamm Bowel Dis       Date:  2011-11-13       Impact factor: 5.325

9.  Orocaecal transit time in patients with Crohn disease.

Authors:  H Götze; A Ptok
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

10.  A Novel Pharmacological Approach to Enhance the Integrity and Accelerate Restitution of the Intestinal Epithelial Barrier.

Authors:  Xuelei Cao; Lei Sun; Susana Lechuga; Nayden G Naydenov; Alex Feygin; Andrei I Ivanov
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.